Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioNTech SE ( (BNTX) ) just unveiled an update.
On September 5, 2025, BioNTech SE and Duality Biologics announced that their Phase 3 trial in China for trastuzumab pamirtecan (BNT323/DB-1303) met its primary endpoint of progression-free survival in patients with HER2-positive metastatic breast cancer. This milestone marks the first positive Phase 3 data from their strategic collaboration, highlighting the potential of trastuzumab pamirtecan as a new treatment option. The success of this trial strengthens BioNTech’s position in oncology and supports further development of the drug in other regions, including the U.S. and EU.
The most recent analyst rating on (BNTX) stock is a Hold with a $120.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects significant financial and technical challenges. While strategic collaborations and revenue growth are positives, the company’s profitability issues and bearish technical indicators weigh heavily on the score. The negative valuation metrics further contribute to a cautious outlook.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases. The company utilizes a variety of computational discovery and therapeutic modalities, including mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and CAR T cell therapies. BioNTech collaborates with several global pharmaceutical companies to advance its diverse oncology pipeline and mRNA vaccine candidates for infectious diseases.
Average Trading Volume: 720,359
Technical Sentiment Signal: Sell
Current Market Cap: $24.88B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.